경보제약

214390KOSPI기초 의약물질 제조업

55.2 / 100

Reference Date: 2026-04-13

Financial Score15.0 / 40

News Sentiment17.2 / 25

Momentum13.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Surged 28.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Gyeongbo Pharm, established in 1987, is a specialty pharmaceutical company specializing in raw material drugs, selling cardiovascular medications, inhalation anesthetics, and general pharmaceuticals. With raw material pharmaceuticals revenue at 137.3 billion KRW and finished pharmaceuticals at 96.8 billion KRW in 2024, the company is preparing to enter the global ADC CDMO market through self-developed technology. It also expands into medical devices and animal health sectors.

Number of Employees

571people

Average Salary

75.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

893.75Industry Average 33.450.0Point

26.7x industry avg (risky)

PBR

1.17Industry Average 2.035.5Point

Lower than industry avg (good)

ROE

0.13Industry Average -4.293.5Point

Well below industry avg

Debt Ratio

18.22Industry Average 6.610.0Point

2.8x industry avg (risky)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲10.5% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲11.1% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 1.8% (declining, 3yr)

Detailed News Sentiment

8 totalPositive 3Neutral 2Negative 0Average Sentiment Score 80

Positive
차백신, 소룩스 훈풍 지속…경보제약 FDA 기대·티움 임상 성과 부각[...
경보제약이 FDA 실사 통과에 따른 글로벌 생산 신뢰도 확보 기대감에 상승세를 보였다는 내용입니다.
Neutral
[서울데이터랩]3월 20일 코스피 주요 종목 마감시황
3월 20일 코스피 주요 종목의 마감 시황을 다루는 뉴스로, 경보제약에 대한 직접적인 내용은 없습니다.
Neutral
‘글로벌 1위’ 다케다 P-CAB 특허 만료 임박…제네릭 공습에 대원제...
다케다 P-CAB 특허 만료 임박으로 제네릭 시장 경쟁이 심화될 것이라는 뉴스로, 경보제약에 대한 직접적인 내용은 없습니다.

Detailed Momentum

52-week position6.0Point

52w upper range (63%)

Current 7,150Won52-week high 8,55052-week low 4,765

1-month return6.0Point

1m +28.83% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral단일판매ㆍ공급계약해지2026-04-10
Neutral기업가치제고계획(자율공시)2026-03-26
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26
Neutral정기주주총회결과2026-03-26
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-19